Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder

By Anderson Rodney   MacDiarmid Scott   Kell Sherron   Barada James   Serels Scott   Goldberg Roger  

International Urogynecology Journal, Vol. 17, Iss. 5, 2006-10 ,pp. : 502-511

Springer Publishing Company

Access to resources Recommend Favorite

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

By Sand Peter   Miklos John   Ritter Henry   Appell Rodney  

International Urogynecology Journal, Vol. 15, Iss. 4, 2004-08 ,pp. : 243-248

Springer Publishing Company

Access to resources Recommend Favorite

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden

By Peeker Ralph   Samsioe Gööran   Kowalski Jan   Andersson Ann-Sofie   Bergqvist Agneta  

Scandinavian Journal of Urology and Nephrology, Vol. 44, Iss. 3, 2010-04 ,pp. : 138-146

Informa Healthcare

Access to resources Recommend Favorite

Comparison of Dry Mouth in Women Treated with Extended-Release Formulations of Oxybutynin or Tolterodine for Overactive Bladder

By Armstrong Robert   Luber Karl   Peters Kenneth  

International Urology and Nephrology, Vol. 37, Iss. 2, 2005-06 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data - oxybutynin versus propantheline versus placebo

By Larsson G.   Hallen B.   Nilvebrant L.  

Urology, Vol. 53, Iss. 5, 1999-05 ,pp. : 990-998

Elsevier

Access to resources Recommend Favorite